middle.news
Why Percheron Therapeutics Is Betting Big on HMBD-002 After $14.9M Loss
2:47am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Why Percheron Therapeutics Is Betting Big on HMBD-002 After $14.9M Loss
2:47am on Saturday 30th of August, 2025 AEST
Key Points
Net loss increased 25% to $14.9 million for FY2025
Discontinued development of ATL1102 and ATL1103 after negative trial results
In-licensed HMBD-002, a monoclonal antibody targeting VISTA for cancer treatment
Cash reserves of $10.2 million with cost reduction measures implemented
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE